Triple Negative Breast Cancer: Molecular Classification, Prognostic Markers and Targeted Therapies

  • سال انتشار: 1394
  • محل انتشار: مجله بین المللی پزشکی رضوی، دوره: 3، شماره: 2
  • کد COI اختصاصی: JR_RIJO-3-2_002
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 305
دانلود فایل این مقاله

نویسندگان

Narges Jafarzadeh

Department of Research and Education, Razavi Hospital, Mashhad, IR Iran

Hami Ashraf

Department of Research and Education, Razavi Hospital, Mashhad, IR Iran- Zakaria Idea and Innovation Support and Leading Center, Tehran, IR Iran

Fahimeh Khoshroo

Department of Research and Education, Razavi Hospital, Mashhad, IR Iran

Alireza Sepehri Shamloo

Student Research Committee, Mashhad University of Medical Sciences, Mashhad, IR Iran

Farzad Bidouei

Department of Research and Education, Razavi Hospital, Mashhad, IR Iran

Kamran Ghaffarzadehgan

Department of Research and Education, Razavi Hospital, Mashhad, IR Iran

چکیده

Context: Triple negative breast cancer (TNBC) is a heterogeneous group of diseases that is negative for esterogen receptor (ER) progesteron receptor (PR) and human epidermal growth factor receptor 2 (HER2). This type of breast cancer is typically high-grade carcinomas, although low-grade tumors occur. The aim of this review is to focus on molecular classification and features, prognostic markers and targeted therapies of triple negative breast cancer.Evidence Acquisition: We searched using electronic databases Pubmed/Medline, Dare, Scopus, Embase, and Cochrane Database of Systematic Reviews with terms of ‘Triple negative breast cancer’, ‘Breast cancer’, ‘Molecular classification’, ‘Immunohistochemical markers’, ‘Molecular features, ‘Targeted therapy’, and ‘Prognostic marker’.Results: It seems that TNBC itself can be subdivided into immunomodulatory, mesenchymal, mesenchymal stem-like, luminal androgen receptor, and distinct basal-like subtypes that differ substantially from basal-like tumors. There are several prognostic makers for TNBC including EGFR and ALDH1, Lysyl Oxidase-Like 2 protein (LOXL2), Synuclein gamma (SNCG), LDHB (Lactate Dehydrogenase B). The antiangiogenic agents, EGFR inhibitors, and PARP inhibitors are new therapeutic Implications and potent factors to targeted therapies of TNBC.Conclusions: Only a few clinical trials are performed on TNBC patients because this disease has a low incidence. Therefore, it seems larger scale clinical trials are needed to be conducted in the future.

کلیدواژه ها

Triple Negative Breast Neoplasms; Molecular Targeted Therapy; Classification; Biological Markers

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.